Treatment of stage 4s neuroblastoma - Report of 10 years' experience of the French Society of Paediatric Oncology (SFOP)

British Journal of Cancer

Volumn 89, Issue 3, 2003, Pages 470-476

  Schleiermacher, G ^a   Rubie, H ^b   Hartmann, O ^c   Bergeron, C ^d   Chastagner, P ^e   Mechinaud, F ^f   Michon, J ^a  

^a INSTITUT CURIE   (France)

^b HÔPITAL DES ENFANTS   (France)

^c INSTITUT GUSTAVE ROUSSY   (France)

^d CENTRE LÉON BÉRARD   (France)

^e Hôpital Mre Enfants   (France)

^f U d'Hemato oncologie Pediat   (France)

Author keywords

Neuroblastoma; Prognosis; Stage 4s; Treatment

Indexed keywords

BUSULFAN; CARBOPLATIN; CARMUSTINE; CATECHOLAMINE; CISPLATIN; CREATININE; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DOPAMINE; DOXORUBICIN; ETOPOSIDE; FERRITIN; HOMOVANILLIC ACID; LACTATE DEHYDROGENASE; MELPHALAN; NEURON SPECIFIC ENOLASE; TENIPOSIDE; VANILMANDELIC ACID; VINCRISTINE; ANTINEOPLASTIC AGENT;

ANEMIA; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER STAGING; CANCER SURVIVAL; CHROMOSOME 1P; CHROMOSOME DELETION; CLINICAL FEATURE; CLINICAL PROTOCOL; CONSERVATIVE TREATMENT; CORRELATION ANALYSIS; DISEASE SEVERITY; DOPAMINE URINE LEVEL; DRUG DOSE REGIMEN; DRUG INDICATION; DRUG MEGADOSE; ENZYME BLOOD LEVEL; ERYTHROCYTE TRANSFUSION; FEMALE; FERRITIN BLOOD LEVEL; FOLLOW UP; FUNCTIONAL DISEASE; GENE AMPLIFICATION; GENETIC MARKER; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INFANT; LIVER METASTASIS; MAJOR CLINICAL STUDY; MALE; NEUROBLASTOMA; NEUTROPENIA; NEWBORN; ONCOGENE C MYB; OUTCOMES RESEARCH; PROGNOSIS; RADIATION DOSE; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; STEM CELL TRANSPLANTATION; SURVIVAL RATE; SYMPTOM; TREATMENT PLANNING; TUMOR LOCALIZATION; TUMOR VOLUME; FRANCE; MEDICAL SOCIETY; PATHOLOGY; PATIENT CARE PLANNING;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CYCLOPHOSPHAMIDE; ETOPOSIDE; FEMALE; FRANCE; GENETIC MARKERS; HUMANS; INFANT; INFANT, NEWBORN; MALE; NEUROBLASTOMA; PATIENT CARE PLANNING; PROGNOSIS; RETROSPECTIVE STUDIES; SOCIETIES, MEDICAL; VINCRISTINE;

EID: 0042978489     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6601154     Document Type: Article

References (25)

1. Bown N, Cotterill S, Lastowska M, O'Neill S, Ellershaw C, Roberts P, Lewis I, Pearson AD, UK Cancer Cytogenetics Group and the UK Children's Cancer Study Group (1999) Gain of chromosome arm 17q and adverse outcome in patients with neuroblastoma. N Engl J Med 340: 1954-1961
2. Brodeur GM, Seeger RC, Barrett A, Berthold F, Castleberry RP, D'Angio G, De Bernardi B, Evans AE, Favrot M, Freeman AI (1988) International criteria for diagnosis, staging, and response to treatment in patients with neuroblastoma. J Clin Oncol 6: 1874-1881
3. Brodeur GM, Pritchard J, Berthold F, Carlsen NL, Castel V, Castelberry RP, De Bernardi B, Evans AE, Favrot M, Hedborg F, Kaneko M, Kemshead J, Lampert F, Lee REJ, Look T, Pearson ADJ, Philip T, Roald B, Sawada T, Seeger R, Tsuchida Y, Voute PA (1993) Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol 11: 1466-1477
4. Caron H (1995) Allelic loss of chromosome 1 and additional chromosome 17 material are both unfavorable prognostic markers in neuroblastoma. Med Pediatr Oncol 24: 215-221
5. De Bernardi B, Pianca C, Boni L, Brisigotti M, Carli M, Bagnulo S, Corciulo P, Mancini A, De Laurentis C, Di Tullio MT, di Montezemolo LC, Lanino E, Clerico A, Rogers DW, Bruzzi P (1992) Disseminated neuroblastoma (stage IV and IV-S) in the first year of life. Outcome related to age and stage. Italian Cooperative Group on Neuroblastoma. Cancer 15: 1625-1633
6. Evans AE, D'Angio GJ, Randoph J (1971) A proposed staging for children with neuroblastoma. Children's Cancer Study Group A. Cancer 27: 374-378
7. Evans AE, Chatten J, D'Angio GJ, Gerson JM, Robinson J, Schnaufer L (1980) A review of 17 IV-S neuroblastoma patients at the Children's Hospital of Philadelphia. Cancer 45: 833-839
8. Evans AE, Silber JH, Shpilsky A, D'Angio GJ (1996) Successful management of low-stage neuroblastoma without adjuvant therapies: a comparison of two decades, 1972 through 1981 and 1982 through 1992, in a single institution. J Clin Oncol 14: 2504-2510
9. Guglielmi M, De Bernardi B, Rizzo A, Federici S, Boglino C, Siracusa F, Leggio A, Cozzi F, Cecchetto G, Musi L, Bardini T, Fagnani AM, Bartoli GC, Pampaloni A, Rogers D, Conte M, Milanaccio C, Bruzzi P (1996) Resection of primary tumor in stage IV-S neuroblastoma: does it affect the clinical course? J Clin Oncol 14: 1537-1544
10. Hartwig NG, Caron HN, den Hollander JC, Robben SG, Egeler RM (1999) Neuroblastoma 4S with an unfavorable biological marker: what to do? Med Pediatr Oncol 32: 294-300
11. Hero B, Simon T, Horz S, Berthold F (2000) Metastatic neuroblastoma in infancy: what does the pattern of metastases contribute to prognosis? Med Pediatr Oncol 35: 683-687
12. Hsu LL, Evans AE, D'Angio GJ (1996) Hepatomegaly in neuroblastoma stage 4s: criteria for treatment of the vulnerable neonate. Med Pediatr Oncol 27: 521-528
13. Katzenstein HM, Bowman LC, Brodeur GM, Thorner PS, Joshi VV, Smith EI, Look AT, Rowe ST, Nash MB, Holbrook T, Alvarado C, Rao PV, Castleberry RP, Cohn SL (1998) Prognostic significance of age, MYCN oncogene amplification, tumor cell ploidy, and histology in 110 infants with stage D(S) neuroblastoma: the Pediatric Oncology Group experience-a Pediatric Oncology Group study. J Clin Oncol 16: 2007-2017
14. Look AT, Hayes FA, Shuster JJ, Douglass EC, Castleberry RP, Bowman LC, Smith EI, Brodeur GM (1991) Clinical relevance of tumor cell ploidy and N-myc amplification in childhood neuroblastoma: a Pediatric Oncology Group study. J Clin Oncol 9: 581-591
15. Mancini AF, Rosito P, Vitelli A, Paolucci P, Vecchi V, Paolucci G, de Bernardi B, Calculli G, Carli M, Castello M (1984) IV-s neuroblastoma: a cooperative study of 30 children. Med Pediatr Oncol 12: 155-161
16. Martinez DA, King DR, Ginn-Pease ME, Haase GM, Wiener ES (1992) Resection of the primary tumor is appropriate for children with stage IV-S neuroblastoma: an analysis of 37 patients. J Pediatr Surgery 27: 1016-1020
17. Matthay KK (1998) Stage 4S neuroblastoma: what makes it special? J Clin Oncol 16: 2003-2006
18. Nickerson HJ, Matthay KK, Seeger RC, Brodeur GM, Shimada H, Perez C, Atkinson JB, Selch M, Gerbing RB, Stram DO, Lukens J (2000) Favorable biology and outcome of stage IV-S neuroblastoma with supportive care or minimal therapy: a Children's Cancer Group study. J Clin Oncol 18: 477-486
19. Pritchard J, Hickman JA (1994) Why does stage 4s neuroblastoma regress spontaneously? Lancet 344: 869-870
20. Rubie H, Plantaz D, Coze C, Michon J, Frappaz D, Baranzelli MC, Chastagner P, Peyroulet MC, Hartmann O, Neuroblastoma Study Group, Societe Francaise d'Oncologie Pediatrique (2001) Localised and unresectable neuroblastoma in infants: excellent outcome with primary chemotherapy. Neuroblastoma Study Group, Société Française d'Oncologie Pédiatrique. Med Pediatr Oncol 36: 247-250
21. Seeger RC, Brodeur GM, Sather H, Dalton A, Siegel SE, Wong KY, Hammond D (1985) Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N Engl J Med 313: 1111-1116
22. Strother D, Shuster JJ, McWilliams N, Nitschke R, Smith EI, Joshi VJ, Kun L, Hayes FA, Castleberry R (1995) Results of pediatric oncology group protocol 8104 for infants with stages D and DS neuroblastoma. J Pediatr Hematol Oncol 17: 254-259
23. Suarez A, Hartmann O, Vassal G, Giron A, Habrand JL, Valteau D, Brugieres L, Kalifa C, Lemerle J (1991) Treatment of stage IV-S neuroblastoma: a study of 34 cases treated between 1982 and 1987. Med Pediatr Oncol 19: 473-477
24. Tonini GP, Boni L, Pession A, Rogers D, Iolascon A, Basso G, Cordero di Montezemolo L, Casale F, Perri P, Mazzocco K, Scaruffi P, Lo Cunsolo C, Marchese N, Milanaccio C, Conte M, Bruzzi P, De Bernardi B (1997) MYCN oncogene amplification in neuroblastoma is associated with worse prognosis, except in stage 4s: the Italian experience with 295 children. J Clin Oncol 15: 85-93
25. Van Noesel MM, Hählen K, Hakvoort-Cammel FGAJ, Egeler RM (1997) Neuroblastoma 4s; a heterogeneous disease with variable risk factors and treatment strategies. Cancer 80: 834-843